APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hypereosinophilic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hypereosinophilic Syndrome Drug Industry Growth and Trends Forecast to 2032

Report ID 174000940119 December 202596 pages

Choose your research edition.

Industry ResearchHypereosinophilic Syndrome Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hypereosinophilic Syndrome Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hypereosinophilic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hypereosinophilic Syndrome Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hypereosinophilic Syndrome Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Hypereosinophilic Syndrome Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hypereosinophilic Syndrome Drug include GlaxoSmithKline Plc, Stemline Therapeutics Inc, Kyowa Hakko Kirin Co Ltd, Knopp Biosciences LLC and Bristol-Myers Squibb Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hypereosinophilic Syndrome Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hypereosinophilic Syndrome Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hypereosinophilic Syndrome Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hypereosinophilic Syndrome Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hypereosinophilic Syndrome Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hypereosinophilic Syndrome Drug Market by Company

GlaxoSmithKline Plc

Stemline Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Knopp Biosciences LLC

Bristol-Myers Squibb Co

Hypereosinophilic Syndrome Drug Segment by Type

Dexpramipexole Dihydrochloride

Mepolizumab

Dasatinib

Benralizumab

Others

Hypereosinophilic Syndrome Drug Segment by Application

Clinic

Hospital

Research Center

Hypereosinophilic Syndrome Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hypereosinophilic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hypereosinophilic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hypereosinophilic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hypereosinophilic Syndrome Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hypereosinophilic Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Dexpramipexole Dihydrochloride Table 2. Major Company of Mepolizumab Table 3. Major Company of Dasatinib Table 4. Major Company of Benralizumab Table 5. Major Company of Others Table 6. Global Hypereosinophilic Syndrome Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 8. Global Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Hypereosinophilic Syndrome Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Hypereosinophilic Syndrome Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Hypereosinophilic Syndrome Drug Sales by Type (2027-2032) & (K Units) Table 13. Global Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Hypereosinophilic Syndrome Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Hypereosinophilic Syndrome Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Hypereosinophilic Syndrome Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 18. North America Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 20. Europe Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 24. Latin America Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Hypereosinophilic Syndrome Drug Industry Trends Table 28. Hypereosinophilic Syndrome Drug Industry Drivers Table 29. Hypereosinophilic Syndrome Drug Industry Opportunities and Challenges Table 30. Hypereosinophilic Syndrome Drug Industry Restraints Table 31. Global Hypereosinophilic Syndrome Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Company (2021-2026) Table 33. Global Hypereosinophilic Syndrome Drug Sales by Company (2021-2026) & (K Units) Table 34. Global Hypereosinophilic Syndrome Drug Sales Share by Company (2021-2026) Table 35. Global Hypereosinophilic Syndrome Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Hypereosinophilic Syndrome Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Hypereosinophilic Syndrome Drug Major Company Production Sites and Headquarters Table 38. Global Hypereosinophilic Syndrome Drug Company, Product Type & Application Table 39. Global Hypereosinophilic Syndrome Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Hypereosinophilic Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Hypereosinophilic Syndrome Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Hypereosinophilic Syndrome Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Hypereosinophilic Syndrome Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Hypereosinophilic Syndrome Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Hypereosinophilic Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Hypereosinophilic Syndrome Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Hypereosinophilic Syndrome Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Hypereosinophilic Syndrome Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Hypereosinophilic Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Hypereosinophilic Syndrome Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Hypereosinophilic Syndrome Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Hypereosinophilic Syndrome Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Hypereosinophilic Syndrome Drug Sales by Application (2027-2032) & (K Units) Table 60. Global Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Hypereosinophilic Syndrome Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Hypereosinophilic Syndrome Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Hypereosinophilic Syndrome Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 65. North America Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 67. Europe Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 71. Latin America Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (US$ Million) Table 74. GlaxoSmithKline Plc Company Information Table 75. GlaxoSmithKline Plc Business Overview Table 76. GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Product Portfolio Table 78. GlaxoSmithKline Plc Recent Development Table 79. Stemline Therapeutics Inc Company Information Table 80. Stemline Therapeutics Inc Business Overview Table 81. Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Product Portfolio Table 83. Stemline Therapeutics Inc Recent Development Table 84. Kyowa Hakko Kirin Co Ltd Company Information Table 85. Kyowa Hakko Kirin Co Ltd Business Overview Table 86. Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Product Portfolio Table 88. Kyowa Hakko Kirin Co Ltd Recent Development Table 89. Knopp Biosciences LLC Company Information Table 90. Knopp Biosciences LLC Business Overview Table 91. Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Product Portfolio Table 93. Knopp Biosciences LLC Recent Development Table 94. Bristol-Myers Squibb Co Company Information Table 95. Bristol-Myers Squibb Co Business Overview Table 96. Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Product Portfolio Table 98. Bristol-Myers Squibb Co Recent Development Table 99. North America Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 100. North America Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 101. North America Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2026) Table 102. North America Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032) & (K Units) Table 103. North America Hypereosinophilic Syndrome Drug Sales Market Share Forecast by Country (2027-2032) Table 104. North America Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 105. North America Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026) & (US$ Million) Table 106. North America Hypereosinophilic Syndrome Drug Market Share by Country (2021-2026) Table 107. North America Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 108. North America Hypereosinophilic Syndrome Drug Market Share Forecast by Country (2027-2032) Table 109. Europe Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 110. Europe Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 111. Europe Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2026) Table 112. Europe Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032) & (K Units) Table 113. Europe Hypereosinophilic Syndrome Drug Sales Market Share Forecast by Country (2027-2032) Table 114. Europe Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 115. Europe Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026) & (US$ Million) Table 116. Europe Hypereosinophilic Syndrome Drug Market Share by Country (2021-2026) Table 117. Europe Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 118. Europe Hypereosinophilic Syndrome Drug Market Share Forecast by Country (2027-2032) Table 119. Asia-Pacific Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 121. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2026) Table 122. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032) & (K Units) Table 123. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Market Share Forecast by Country (2027-2032) Table 124. Asia-Pacific Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. Asia-Pacific Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026) & (US$ Million) Table 126. Asia-Pacific Hypereosinophilic Syndrome Drug Market Share by Country (2021-2026) Table 127. Asia-Pacific Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. Asia-Pacific Hypereosinophilic Syndrome Drug Market Share Forecast by Country (2027-2032) Table 129. Latin America Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Latin America Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 131. Latin America Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2026) Table 132. Latin America Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032) & (K Units) Table 133. Latin America Hypereosinophilic Syndrome Drug Sales Market Share Forecast by Country (2027-2032) Table 134. Latin America Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Latin America Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026) & (US$ Million) Table 136. Latin America Hypereosinophilic Syndrome Drug Market Share by Country (2021-2026) Table 137. Latin America Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Latin America Hypereosinophilic Syndrome Drug Market Share Forecast by Country (2027-2032) Table 139. Middle East and Africa Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 141. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2026) Table 142. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032) & (K Units) Table 143. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share Forecast by Country (2027-2032) Table 144. Middle East and Africa Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Middle East and Africa Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Hypereosinophilic Syndrome Drug Market Share by Country (2021-2026) Table 147. Middle East and Africa Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Middle East and Africa Hypereosinophilic Syndrome Drug Market Share Forecast by Country (2027-2032) Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Hypereosinophilic Syndrome Drug Distributors List Table 152. Hypereosinophilic Syndrome Drug Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Hypereosinophilic Syndrome Drug Image Figure 2. Global Hypereosinophilic Syndrome Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hypereosinophilic Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hypereosinophilic Syndrome Drug Sales (2021-2032) & (K Units) Figure 5. Dexpramipexole Dihydrochloride Image Figure 6. Global Dexpramipexole Dihydrochloride Sales YoY Growth (2021-2032) & (K Units) Figure 7. Mepolizumab Image Figure 8. Global Mepolizumab Sales YoY Growth (2021-2032) & (K Units) Figure 9. Dasatinib Image Figure 10. Global Dasatinib Sales YoY Growth (2021-2032) & (K Units) Figure 11. Benralizumab Image Figure 12. Global Benralizumab Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Hypereosinophilic Syndrome Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Hypereosinophilic Syndrome Drug Market Share by Type 2025 VS 2032 Figure 17. North America Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Hypereosinophilic Syndrome Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Hypereosinophilic Syndrome Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Hypereosinophilic Syndrome Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Hypereosinophilic Syndrome Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 33. Research Center Image Figure 34. Global Research Center Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Hypereosinophilic Syndrome Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Hypereosinophilic Syndrome Drug Market Share by Application 2025 VS 2032 Figure 37. North America Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Hypereosinophilic Syndrome Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Hypereosinophilic Syndrome Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Hypereosinophilic Syndrome Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Hypereosinophilic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Hypereosinophilic Syndrome Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Hypereosinophilic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Hypereosinophilic Syndrome Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Hypereosinophilic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Hypereosinophilic Syndrome Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Hypereosinophilic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Hypereosinophilic Syndrome Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Hypereosinophilic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Hypereosinophilic Syndrome Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Hypereosinophilic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Hypereosinophilic Syndrome Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Hypereosinophilic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Hypereosinophilic Syndrome Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Hypereosinophilic Syndrome Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Hypereosinophilic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Hypereosinophilic Syndrome Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Hypereosinophilic Syndrome Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Hypereosinophilic Syndrome Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Dexpramipexole Dihydrochloride
  • Mepolizumab
  • Dasatinib
  • Benralizumab
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
Companies covered
  • GlaxoSmithKline Plc
  • Stemline Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • Knopp Biosciences LLC
  • Bristol-Myers Squibb Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hypereosinophilic Syndrome Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hypereosinophilic Syndrome Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hypereosinophilic Syndrome Drug Market by Type
  6. 1.3.1 Dexpramipexole Dihydrochloride
  7. 1.3.2 Mepolizumab
  8. 1.3.3 Dasatinib
  9. 1.3.4 Benralizumab
  10. 1.3.5 Others
  11. 1.4 Global Hypereosinophilic Syndrome Drug Market Size by Type
  12. 1.4.1 Global Hypereosinophilic Syndrome Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Hypereosinophilic Syndrome Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Hypereosinophilic Syndrome Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Hypereosinophilic Syndrome Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Hypereosinophilic Syndrome Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Hypereosinophilic Syndrome Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Hypereosinophilic Syndrome Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Hypereosinophilic Syndrome Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hypereosinophilic Syndrome Drug Industry Trends
  2. 2.2 Hypereosinophilic Syndrome Drug Industry Drivers
  3. 2.3 Hypereosinophilic Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Hypereosinophilic Syndrome Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hypereosinophilic Syndrome Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Hypereosinophilic Syndrome Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Hypereosinophilic Syndrome Drug Price (2021-2026)
  4. 3.4 Global Hypereosinophilic Syndrome Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hypereosinophilic Syndrome Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Hypereosinophilic Syndrome Drug Company, Product Type & Application
  7. 3.7 Global Hypereosinophilic Syndrome Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hypereosinophilic Syndrome Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hypereosinophilic Syndrome Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hypereosinophilic Syndrome Drug Tier 1, Tier 2, and Tier 3
4 Hypereosinophilic Syndrome Drug Regional Status and Outlook
  1. 4.1 Global Hypereosinophilic Syndrome Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hypereosinophilic Syndrome Drug Historic Market Size by Region
  3. 4.2.1 Global Hypereosinophilic Syndrome Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hypereosinophilic Syndrome Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hypereosinophilic Syndrome Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hypereosinophilic Syndrome Drug Forecasted Market Size by Region
  7. 4.3.1 Global Hypereosinophilic Syndrome Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hypereosinophilic Syndrome Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hypereosinophilic Syndrome Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hypereosinophilic Syndrome Drug by Application
  1. 5.1 Hypereosinophilic Syndrome Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.2 Global Hypereosinophilic Syndrome Drug Market Size by Application
  6. 5.2.1 Global Hypereosinophilic Syndrome Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hypereosinophilic Syndrome Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hypereosinophilic Syndrome Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hypereosinophilic Syndrome Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hypereosinophilic Syndrome Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hypereosinophilic Syndrome Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hypereosinophilic Syndrome Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hypereosinophilic Syndrome Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GlaxoSmithKline Plc
  2. 6.1.1 GlaxoSmithKline Plc Company Information
  3. 6.1.2 GlaxoSmithKline Plc Business Overview
  4. 6.1.3 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Product Portfolio
  6. 6.1.5 GlaxoSmithKline Plc Recent Developments
  7. 6.2 Stemline Therapeutics Inc
  8. 6.2.1 Stemline Therapeutics Inc Company Information
  9. 6.2.2 Stemline Therapeutics Inc Business Overview
  10. 6.2.3 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Product Portfolio
  12. 6.2.5 Stemline Therapeutics Inc Recent Developments
  13. 6.3 Kyowa Hakko Kirin Co Ltd
  14. 6.3.1 Kyowa Hakko Kirin Co Ltd Company Information
  15. 6.3.2 Kyowa Hakko Kirin Co Ltd Business Overview
  16. 6.3.3 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Product Portfolio
  18. 6.3.5 Kyowa Hakko Kirin Co Ltd Recent Developments
  19. 6.4 Knopp Biosciences LLC
  20. 6.4.1 Knopp Biosciences LLC Company Information
  21. 6.4.2 Knopp Biosciences LLC Business Overview
  22. 6.4.3 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Product Portfolio
  24. 6.4.5 Knopp Biosciences LLC Recent Developments
  25. 6.5 Bristol-Myers Squibb Co
  26. 6.5.1 Bristol-Myers Squibb Co Company Information
  27. 6.5.2 Bristol-Myers Squibb Co Business Overview
  28. 6.5.3 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Product Portfolio
  30. 6.5.5 Bristol-Myers Squibb Co Recent Developments
7 North America by Country
  1. 7.1 North America Hypereosinophilic Syndrome Drug Sales by Country
  2. 7.1.1 North America Hypereosinophilic Syndrome Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hypereosinophilic Syndrome Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hypereosinophilic Syndrome Drug Market Size by Country
  6. 7.2.1 North America Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hypereosinophilic Syndrome Drug Sales by Country
  2. 8.1.1 Europe Hypereosinophilic Syndrome Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hypereosinophilic Syndrome Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hypereosinophilic Syndrome Drug Market Size by Country
  6. 8.2.1 Europe Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Country
  2. 9.1.1 Asia-Pacific Hypereosinophilic Syndrome Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hypereosinophilic Syndrome Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hypereosinophilic Syndrome Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hypereosinophilic Syndrome Drug Sales by Country
  2. 10.1.1 South America Hypereosinophilic Syndrome Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hypereosinophilic Syndrome Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hypereosinophilic Syndrome Drug Market Size by Country
  6. 10.2.1 South America Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country
  2. 11.1.1 Middle East and Africa Hypereosinophilic Syndrome Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hypereosinophilic Syndrome Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hypereosinophilic Syndrome Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Hypereosinophilic Syndrome Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hypereosinophilic Syndrome Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hypereosinophilic Syndrome Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hypereosinophilic Syndrome Drug Value Chain Analysis
  2. 12.1.1 Hypereosinophilic Syndrome Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hypereosinophilic Syndrome Drug Production Mode & Process
  7. 12.2 Hypereosinophilic Syndrome Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hypereosinophilic Syndrome Drug Distributors
  10. 12.2.3 Hypereosinophilic Syndrome Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst